ReGenTree, LLC
Industry
- Diversified
- Pharmaceuticals
Other Names/Subsidiaries
- GtreeBNT Co., Ltd.
- Oblato, Inc.
- RegeneRx Biopharmaceuticals, Inc.
Latest on ReGenTree, LLC
HanAll BioPharma Co. Ltd. and Daewoong Pharmaceutical Co. Ltd. have unveiled top-line results from the first US Phase III study for HL036, their investigational biologic for the treatment of dry ey
[Johnson & Johnson Innovation - JLABS] has been launching its JLABS sites within biotechnology hubs such as Boston, San Diego and San Francisco since 2012, but it chose Philadelphia as the site for it
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in
Although the FDA has accepted all safety data from two Phase III trials of dry eye treatment candidate RGN-259, the agency wants the drug's backers to conduct an additional Phase III trial to further